Survival Analysis and Prognosis for Patients with Serous and Mucinous Borderline Ovarian Tumors: 14-Year Experience from a Tertiary Center in Iran

The aim of this study was to determine the prognosis and survival for patients with borderline ovarian tumor (bot). a retrospective review of 30 patients with serous and mucinous bot treated at or referred to our institution was performed. fifteen patients (50%) had serous, and the others had mucinous bot. about 86% of all patients in both groups were in stage i of the disease. the recurrent disease occurred in 7% and 21% of serous and mucinous tumors, respectively. all recurrences, except one in mucinous tumors, were found in advance stage disease. after a mean of 37 and 52 months follow-up, the overall survival was 100% and 93%, and disease-free survival was 93% and 79% for serous and mucinous tumors, respectively. in this series, advanced stage was associated with poor prognosis. however, to obtain more accurate information further studies with number of patients and longer follow-up is recommended.